Audentes to build gene therapy plant in North Carolina

Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research

Related Links:

Publication date: Available online 8 April 2020Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Yongho Jang, Doyeon Kim, Hohyeon Lee, Hyejin Jang, Suhyeon Park, Ga Eul Kim, Hak Jong Lee, Hyun Jung Kim, Hyuncheol Kim
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
Medical centers across the country have slowed or stopped the enrollment of new patients in mesothelioma clinical trials because of the all-consuming COVID-19 pandemic. The pause in enrollment options could be critical for newly diagnosed patients with pleural mesothelioma, whose life expectancy is often just six to 12 months. Clinical trials are research studies where patients can find cutting-edge treatments not yet approved by the U.S. Food and Drug Administration. Those experimental treatments go beyond standard of care, which generally has not been effective for this rare and aggressive cancer caused by asbestos expos...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
lli G Abstract Recent comparisons between plant and animal viruses reveal many common principles that underlie how all viruses express their genetic material, amplify their genomes, and link virion assembly with replication. Cauliflower mosaic virus (CaMV) is not infectious for human beings. Here, we show that CaMV transactivator/viroplasmin protein (TAV) shares sequence similarity with and behaves like the human ribonuclease H1 (RNase H1) in reducing DNA/RNA hybrids detected with S9.6 antibody in HEK293T cells. We showed that TAV is clearly expressed in the cytosol and in the nuclei of transiently transfected hum...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Research into cancer, heart disease, HIV, MS, Alzheimer ’s, gene therapy, opioid addiction, epilepsy, blindness — all abruptly stopped in mid-March.
Source: Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Conclusions: Our results indicate that a moderate increase in PDE4B is cardioprotective and suggest that cardiac gene therapy with PDE4B might constitute a new promising approach to treat HF. PMID: 32264695 [PubMed - as supplied by publisher]
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Journal of Ocular Pharmacology and Therapeutics, Ahead of Print.
Source: Journal of Ocular Pharmacology and Therapeutics - Category: Opthalmology Authors: Source Type: research
Purpose of review The available vaccine and therapies against hepatitis B virus (HBV) rarely eliminate chronic infection with the virus. High mortality resulting from complicating cirrhosis and hepatocellular carcinoma makes improving anti-HBV therapy an important priority. Recent advances with using gene therapy to counter HBV have potential and are the focus of this review. Recent findings The stable replication-competent HBV intermediate comprising covalently closed circular DNA (cccDNA) is the template for expression of all viral genes. Inactivating cccDNA has thus been a focus of research aimed at achieving cure ...
Source: Current Opinion in HIV and AIDS - Category: Infectious Diseases Tags: HIV AND HEPATITIS B CURE: Edited by Sharon R. Lewin and Peter A. Revill Source Type: research
This article is protected by copyright. All rights reserved
Source: Biotechnology and Applied Biochemistry - Category: Biochemistry Authors: Tags: Review Article Source Type: research
CONCLUSIONS: Treatment with VB-111 in combination with paclitaxel was safe and well tolerated. Favorable tumor responses and overall survival outcomes were associated with induction of an immunotherapeutic effect. PMID: 32265057 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
Abstract The last few years have witnessed a great advance in the development of nonviral systems for in vivo targeted delivery of nucleic acids. Lipid nanoparticles (LNPs) are the most promising carriers for producing clinically approved products in the future. Compared with other systems used for nonviral gene delivery, LNPs provide several advantages including higher stability, low toxicity, and greater efficiency. Additionally, systems based on LNPs can be modified with ligands and devices for controlled biodistribution and internalization into specific cells. Efforts are ongoing to improve the efficiency of l...
Source: Biological and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Tags: Biol Pharm Bull Source Type: research
More News: Chemistry | Gene Therapy | Genetics